Street:4620 Technology Drive, Suite 600 Golden, CO 80403
MaxCard:
About us
Welcome To Our Site!
Our commitment to our customers has helped ABR – Affinity BioReagents to become one of the leading life science reagents suppliers in the world. We greatly appreciate your support over the years, and we are proud of our 19-year history of exceeding customer requirements by providing quality antibody-based technologies.
As you know, the research and drug discovery environment we share is rapidly changing, and to continue to excel we must keep pace with this change and the opportunities that emerge. Thermo Fisher Scientific, the world leader in serving service, has acquired ABR – Affinity BioReagents. With annual revenues of $10 billion, Thermo Fisher Scientific has more that 30,000 employees and serves over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. The ABR – Affinity BioReagents product line will be integrated into the Thermo Scientific product portfolio, which includes other product lines such as Pierce Protein Research Products, Dharmacon RNA Technologies and HyClone Cell Culture.
ABR – Affinity BioReagents has maintained a strong and growing relationship with Fisher Scientific, part of Thermo Fisher Scientific, as a channel sales partner science 2004. This transaction is an evolution in that important strategic relationship and will provide the resources to further leverage our antibody-based technologies.
This change will benefit valued customers like you. The market and financial strength of Thermo Fisher Scientific strengthens our ability to innovate and quickly respond to your needs and the evolving demands of the industry. You should have the utmost confidence that the high-quality products, services and technical support you have come to expect from ABR – Affinity BioReagents will continue.
During the coming weeks and months, our team will provide additional information to you about the exciting change. Please know that we remain committed to you, to your research and to answering any questions you may have about this acquisition and how it will benefit your research.
This is an exciting time for all of us, and we are confident about the future as we continue to focus on your research challenges. Thank you for your ongoing support, and we look forward to continuing to serve you.
Ken Wilczek
General Manager
ABR – Affinity BioReagents Products
ken.wilczek@thermofisher.com
United States
